$AGIO News Article - Agios Receives FDA Breakthrough Therapy Designation for TIBSOVO (ivosidenib) in Combination with Azacitidine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) with an IDH1 Mutation in Adult Patients Ineligible for Intensive Chemother
https://marketwirenews.com/news-releases/agio...94126.html